Condition: Metastatic Castration-Resistant Prostate Cancer · Sponsor: Novartis Pharmaceuticals
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| University of California LA | Los Angeles, California, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Wash U School of Medicine | St Louis, Missouri, United States | Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| Novartis Investigative Site | Cologne, North Rhine-Westphalia, Germany | Recruiting |
| Novartis Investigative Site | Wuppertal, North Rhine-Westphalia, Germany | Recruiting |
| Novartis Investigative Site | Aachen, Germany | Recruiting |
| Novartis Investigative Site | Berlin, Germany | Recruiting |
| Novartis Investigative Site | Essen, Germany | Recruiting |
| Novartis Investigative Site | München, Germany | Recruiting |
| Novartis Investigative Site | Rostock, Germany | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06531499